Should You Buy Kiniksa Pharmaceuticals International PLC (KNSA) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
43.280
1 Day change
-3.05%
52 Week Range
45.000
Analysis Updated At
2026/01/26
Kiniksa Pharmaceuticals International PLC (KNSA) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show a bullish trend and analysts have raised the price target with a Buy rating, the company's financial performance shows significant challenges with a sharp decline in net income and EPS. Additionally, there are no recent news catalysts or significant insider/hedge fund activity to support a strong buy decision. The options data suggests low bearish sentiment, but this alone is not enough to justify immediate action.
Technical Analysis
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 42.517), which may limit short-term upside potential.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
The options data indicates a low put-call ratio, suggesting minimal bearish sentiment. However, the implied volatility is relatively high (57.85), and the IV percentile is low (28.8), indicating limited options trading activity.
Technical Summary
Sell
3
Buy
10
Positive Catalysts
Goldman Sachs raised the price target to $55 from $45 with a Buy rating.
Revenue increased significantly by 61.17% YoY in Q3
Gross margin improved to 88.8%, up 8.19% YoY.
Neutral/Negative Catalysts
Net income dropped significantly by -245.24% YoY in Q3
EPS fell by -227.78% YoY, indicating poor profitability.
No recent news or significant insider/hedge fund activity to support a strong buy decision.
Financial Performance
In Q3 2025, revenue grew by 61.17% YoY to $180.86M, and gross margin improved to 88.8%. However, net income dropped by -245.24% YoY to $18.44M, and EPS declined by -227.78% YoY to $0.23, reflecting profitability challenges.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Goldman Sachs recently raised the price target to $55 from $45 and maintained a Buy rating, indicating positive sentiment from analysts.
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 53.5 USD with a low forecast of 48 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 53.5 USD with a low forecast of 48 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.640
Low
48
Averages
53.5
High
60
Current: 44.640
Low
48
Averages
53.5
High
60
Goldman Sachs
Buy
upgrade
$45 -> $55
AI Analysis
2025-10-29
Reason
Goldman Sachs
Price Target
$45 -> $55
AI Analysis
2025-10-29
upgrade
Buy
Reason
Goldman Sachs raised the firm's price target on Kiniksa to $55 from $45 and keeps a Buy rating on the shares.
Citi
Geoff Meacham
Buy
maintain
$45 -> $50
2025-10-17
Reason
Citi
Geoff Meacham
Price Target
$45 -> $50
2025-10-17
maintain
Buy
Reason
Citi analyst Geoff Meacham raised the firm's price target on Kiniksa to $50 from $45 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KNSA
